Abstract
Levosimendan, a Ca2+ sensitizer, has emerged as an alternative option of pharmacologic inotropic support in patients with decompensated heart failure. In contrast to classic inotropes, rather than interfering with intracellular Ca2+ levels in myocytes, levosimendan improves cardiac performance via Ca2+ sensitization and K+ channel-mediated peripheral vasodilatation. A two compartment pharmacokinetic model with zero-order input and first-order elimination has been found to describe best the pharmacokinetics of levosimendan. Although oral levosimendan has high bioavailability (≉85%), in clinical practice it has been hitherto administered intravenously. Levosimendan has total clearance 175-250 mL/h/kg and most importantly a short half-life (about 1.5 hours). Therefore, this drug has a special pharmacokinetic interest: It is one of the few drugs used in cardiovascular medicine, whose prolonged action is not due to the drug itself but it is mainly due to its active metabolite OR-1896 (∼80 hours half life). Other metabolites with possible pharmacologic effect are N-conjugated OR-1855 (M7), N-hydroxylated OR-1855 (M8), N-hydroxylated OR-1896 (M10), O-glucuronide OR-1896 (M9) and O-sulfate (M11) of N-hydroxylated OR-1896. Initial reports on levosimendans use in severe heart failure were positive and levosimendan has already been routinely used for the treatment of patients with decompensated heart failure, while it has been included to the European Society of Cardiology guidelines for the treatment of acute heart failure (class of recommendation IIb, level of evidence B). However, recent clinical trials have failed to demonstrate a clear benefit of levosimendan on survival, compared to other classic inotropic agents in patients requiring inotropic support. In this review article we provide a pharmacokinetic approach for the use of levosimendan in cardiovascular system by discussing its metabolism and mainly the pharmacology of its active metabolites in humans.
Keywords: Levosimendan, Ca2+ sensitizers, pharmacokinetics, metabolism, heart failure
Current Drug Metabolism
Title: Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System
Volume: 10 Issue: 2
Author(s): Charalambos Antoniades, Alexios S. Antonopoulos, Dimitris Tousoulis, Constantinos Bakogiannis, Elli Stefanadi and Christodoulos Stefanadis
Affiliation:
Keywords: Levosimendan, Ca2+ sensitizers, pharmacokinetics, metabolism, heart failure
Abstract: Levosimendan, a Ca2+ sensitizer, has emerged as an alternative option of pharmacologic inotropic support in patients with decompensated heart failure. In contrast to classic inotropes, rather than interfering with intracellular Ca2+ levels in myocytes, levosimendan improves cardiac performance via Ca2+ sensitization and K+ channel-mediated peripheral vasodilatation. A two compartment pharmacokinetic model with zero-order input and first-order elimination has been found to describe best the pharmacokinetics of levosimendan. Although oral levosimendan has high bioavailability (≉85%), in clinical practice it has been hitherto administered intravenously. Levosimendan has total clearance 175-250 mL/h/kg and most importantly a short half-life (about 1.5 hours). Therefore, this drug has a special pharmacokinetic interest: It is one of the few drugs used in cardiovascular medicine, whose prolonged action is not due to the drug itself but it is mainly due to its active metabolite OR-1896 (∼80 hours half life). Other metabolites with possible pharmacologic effect are N-conjugated OR-1855 (M7), N-hydroxylated OR-1855 (M8), N-hydroxylated OR-1896 (M10), O-glucuronide OR-1896 (M9) and O-sulfate (M11) of N-hydroxylated OR-1896. Initial reports on levosimendans use in severe heart failure were positive and levosimendan has already been routinely used for the treatment of patients with decompensated heart failure, while it has been included to the European Society of Cardiology guidelines for the treatment of acute heart failure (class of recommendation IIb, level of evidence B). However, recent clinical trials have failed to demonstrate a clear benefit of levosimendan on survival, compared to other classic inotropic agents in patients requiring inotropic support. In this review article we provide a pharmacokinetic approach for the use of levosimendan in cardiovascular system by discussing its metabolism and mainly the pharmacology of its active metabolites in humans.
Export Options
About this article
Cite this article as:
Antoniades Charalambos, Antonopoulos S. Alexios, Tousoulis Dimitris, Bakogiannis Constantinos, Stefanadi Elli and Stefanadis Christodoulos, Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System, Current Drug Metabolism 2009; 10 (2) . https://dx.doi.org/10.2174/138920009787522142
DOI https://dx.doi.org/10.2174/138920009787522142 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry The Role of STAT 3 in Tissue Fibrosis
Current Chemical Biology Ca2+ Signaling, Mitochondria and Cell Death
Current Molecular Medicine Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Metabolic Effects of Renal Denervation
Current Clinical Pharmacology Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology Editorial [Hot topic: Cardioembolic Infarction: A Renewed Topic of Interest (Guest Editor: Adria Arboix)]
Current Cardiology Reviews